** ASX-listed shares of medical device-maker ResMed RMD.AX fall as much as 7.3% to A$36.02, their lowest level since April 24
** Stock of co, which is involved in treating sleep apnea, COPD and other chronic diseases, marks biggest intraday pct loss since March 12
** RMD is the top pct loser on the ASX 200 benchmark
** Rival Apnimed, which is unlisted, announced positive topline results in first phase 3 clinical trial of AD109, an oral pill for obstructive sleep apnea
** Stock up 0.6% YTD
(Reporting by Sneha Kumar in Bengaluru)
((Sneha.kumar@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。